Co-Authors
This is a "connection" page, showing publications co-authored by Alessio Mazzoni and Alessandro Bartoloni.
Connection Strength
1.213
-
First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. J Clin Invest. 2021 06 15; 131(12).
Score: 0.238
-
Heterogeneous magnitude of immunological memory to SARS-CoV-2 in recovered individuals. Clin Transl Immunology. 2021; 10(5):e1281.
Score: 0.236
-
Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients. Eur J Immunol. 2020 Dec; 50(12):2013-2024.
Score: 0.228
-
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. 2020 09 01; 130(9):4694-4703.
Score: 0.225
-
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib. Am J Hematol. 2021 11 01; 96(11):E408-E410.
Score: 0.060
-
Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab. PLoS Pathog. 2021 02; 17(2):e1009243.
Score: 0.058
-
Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection. Immunology. 2020 12; 161(4):345-353.
Score: 0.057
-
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia. 2021 04; 35(4):1121-1133.
Score: 0.056
-
Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study. J Allergy Clin Immunol Pract. 2020 Sep; 8(8):2575-2581.e2.
Score: 0.055